Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals

Chinese biopharma stocks increased on Monday following a report that the U.S. may permit most pharmaceutical licensing agreements with Chinese companies to proceed. The potential continued access to U.S. markets would affect drugmakers' ability to license treatments and technology across borders. No official announcement from U.S. government agencies was reported at the time of the stock movement.

Next story